Top 10 Companies in the Pharmaceutical Grade Monoammonium Glycyrrhizinate Market (2026): Market Leaders Powering Global Pharmaceutical Supply

This research report provides a comprehensive analysis of the Pharmaceutical Grade Monoammonium Glycyrrhizinate market, focusing on the current trends, market dynamics, and future prospects.

Pharmaceutical Grade Monoammonium Glycyrrhizinate Market – View in Detailed Research Report

The Global Pharmaceutical Grade Monoammonium Glycyrrhizinate market was valued at USD 150 million in 2025 and is projected to reach USD 300 million by 2034, at a CAGR of 6% during the forecast period.

Pharmaceutical Grade Monoammonium Glycyrrhizinate is a purified extract derived from licorice root, formulated to meet stringent pharmaceutical standards. It is employed in a range of dosage forms, including injections, tablets, and topical preparations, offering anti‑inflammatory and antiviral properties that align with contemporary therapeutic demands.

🔟 1. VITAL‑CHEM Zhuhai

Headquarters: Zhuhai, China
Key Offering: High‑purity Monoammonium Glycyrrhizinate for injection and tablet formulations

VITAL‑CHEM has positioned itself as a leading supplier in the Asian market by leveraging advanced purification technologies that reduce impurities to below 0.1%. Their focus on scalable production has enabled consistent supply to major pharmaceutical manufacturers.

Sustainability and Growth Initiatives:

• Investment in renewable energy sources for production facilities.
• Collaboration with academic institutions to streamline R&D pipelines.
• Implementation of a circular waste‑management system for by‑products.

🔟 2. Sabinsa

Headquarters: Hyderabad, India
Key Offering: Bulk and finished‑dose Monoammonium Glycyrrhizinate for oral and injectable use

Sabinsa’s diversified product portfolio caters to both emerging and established markets. Their strategic acquisitions in the biotech sector have broadened the application scope of the compound into nutraceuticals.

Sustainability and Growth Initiatives:

• Deployment of solar power across manufacturing plants.
• Partnerships with NGOs to promote fair‑trade sourcing of licorice root.
• Development of a low‑cost formulation for low‑income markets.

🔟 3. Alchem International

Headquarters: Dublin, Ireland
Key Offering: Ultra‑pure Monoammonium Glycyrrhizinate for injectable therapy

Alchem’s focus on precision chemistry has yielded a product with exceptional batch consistency, appealing to regulatory bodies in the EU and the US. Their R&D pipeline includes derivatives aimed at enhancing bioavailability.

Sustainability and Growth Initiatives:

• Adoption of green chemistry protocols to minimize hazardous waste.
• Engagement with local farmers to secure sustainable raw‑material supply.
• Launch of a digital platform for real‑time quality monitoring.

🔟 4. Shaanxi Fujie Pharmaceutical

Headquarters: Xi’an, China
Key Offering: Bulk Monoammonium Glycyrrhizinate for injection and tablet production

With a robust manufacturing footprint across China, Shaanxi Fujie has cultivated strong ties with regional hospitals. Their emphasis on cost efficiency has made their product attractive to mid‑tier manufacturers.

Sustainability and Growth Initiatives:

• Implementation of water‑recycling systems in production lines.
• Collaboration with government programs to support rural cultivation of licorice root.
• Investment in automation to reduce labor costs.

🔟 5. MAFCO Worldwide

Headquarters: London, United Kingdom
Key Offering: High‑purity Monoammonium Glycyrrhizinate for pharmaceutical and nutraceutical use

MAFCO’s global distribution network ensures timely delivery to key markets in North America and Europe. Their portfolio includes a range of formulations tailored to specific therapeutic indications.

Sustainability and Growth Initiatives:

• Launch of a carbon‑offset program for logistics.
• Development of biodegradable packaging for tablets.
• Participation in EU research grants for natural product development.

🔟 6. Alps Pharmaceutical

Headquarters: Munich, Germany
Key Offering: Bulk and finished‑dose Monoammonium Glycyrrhizinate for injectable therapy

Alps has built a reputation for stringent quality controls, aligning with the European Medicines Agency standards. Their product is favored by specialty pharmacies that require high‑grade excipients.

Sustainability and Growth Initiatives:

• Adoption of energy‑efficient manufacturing processes.
• Engagement with local growers to reduce transportation emissions.
• Exploration of synthetic biology approaches to produce the active compound.

🔟 7. BGG World

Headquarters: Singapore
Key Offering: Bulk Monoammonium Glycyrrhizinate for injection and tablet formulations

BGG World’s strategic positioning in Southeast Asia has enabled rapid market penetration. Their focus on product standardization has eased regulatory approvals across multiple jurisdictions.

Sustainability and Growth Initiatives:

• Implementation of a zero‑waste policy in manufacturing.
• Collaboration with ASEAN health ministries to promote natural therapeutics.
• Investment in digital supply‑chain transparency.

🔟 8. Qingdao Taitong Pharmaceutical

Headquarters: Qingdao, China
Key Offering: High‑purity Monoammonium Glycyrrhizinate for injection and tablet use

Qingdao Taitong has expanded its production capacity through a series of strategic acquisitions, allowing it to serve both domestic and export markets. Their product is known for its low impurity profile.

Sustainability and Growth Initiatives:

• Adoption of renewable energy in manufacturing plants.
• Partnerships with local farmers to ensure traceable sourcing.
• Development of a mobile app for real‑time batch tracking.

🔟 9. Jiangsu Tiansheng Pharmaceutical

Headquarters: Nanjing, China
Key Offering: Bulk Monoammonium Glycyrrhizinate for injection and tablet production

Jiangsu Tiansheng has leveraged its extensive distribution network to penetrate markets in East Asia. Their focus on process optimization has reduced production costs while maintaining quality.

Sustainability and Growth Initiatives:

• Implementation of a green chemistry framework.
• Collaboration with universities for advanced extraction techniques.
• Adoption of AI‑driven quality control systems.

🔟 10. Longtong Pharma

Headquarters: Shanghai, China
Key Offering: Bulk and finished‑dose Monoammonium Glycyrrhizinate for injection and tablet formulations

Longtong Pharma’s emphasis on research has produced a range of derivatives aimed at improving solubility and patient compliance. Their products are widely used in both domestic and international markets.

Sustainability and Growth Initiatives:

• Deployment of water‑saving technologies in production.
• Engagement with local communities to promote sustainable agriculture.
• Launch of a digital platform for supply‑chain traceability.

Download FREE Sample Report

Get Full Report

---

🌍 Outlook: The Future of Pharmaceutical Grade Monoammonium Glycyrrhizinate Is Expanding

The market is moving beyond traditional supply chains, with a shift toward integrated R&D and manufacturing models that reduce lead times. Regulatory emphasis on natural product safety is encouraging manufacturers to adopt stricter quality controls, while consumer preference for plant‑based therapeutics is sustaining demand.

📈 Key Trends Shaping the Market:

• Expansion of high‑purity production facilities in Asia and Europe.
• Increased focus on sustainable cultivation of licorice root.
• Adoption of digital tools for real‑time quality assurance.
• Strategic alliances between pharmaceutical companies and natural‑product suppliers.

These developments position the market for continued advancement, with opportunities for players who can combine technological innovation with sustainable sourcing.